Cargando…

KIT (CD117) Expression in Benign and Malignant Sweat Gland Tumors

KIT (CD117, c-kit) is a receptor tyrosine kinase involved in the tumorigenesis of several neoplasms. KIT is expressed by the secretory cells of normal sweat glands. We studied the KIT expression and KIT mutational status in various benign and malignant tumors of eccrine and apocrine glands. We inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishida, Haruto, Daa, Tsutomu, Kashima, Kenji, Arakane, Motoki, Urabe, Shogo, Yoshikawa, Yasuji, Gamachi, Ayako, Yokoyama, Shigeo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Journal of Dermatopathology 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894802/
https://www.ncbi.nlm.nih.gov/pubmed/25634571
http://dx.doi.org/10.1097/DAD.0000000000000301
_version_ 1782435725661175808
author Nishida, Haruto
Daa, Tsutomu
Kashima, Kenji
Arakane, Motoki
Urabe, Shogo
Yoshikawa, Yasuji
Gamachi, Ayako
Yokoyama, Shigeo
author_facet Nishida, Haruto
Daa, Tsutomu
Kashima, Kenji
Arakane, Motoki
Urabe, Shogo
Yoshikawa, Yasuji
Gamachi, Ayako
Yokoyama, Shigeo
author_sort Nishida, Haruto
collection PubMed
description KIT (CD117, c-kit) is a receptor tyrosine kinase involved in the tumorigenesis of several neoplasms. KIT is expressed by the secretory cells of normal sweat glands. We studied the KIT expression and KIT mutational status in various benign and malignant tumors of eccrine and apocrine glands. We included a total of 108 cases comprising 10 benign and 6 malignant sweat gland tumors, and KIT expression was immunohistochemically detected (positive rate): 10 syringomas (0%), 8 poromas (25%), 20 mixed tumors (40%), 21 spiradenomas (43%), 1 cylindroma (0%), 5 hidradenomas (40%), 7 syringocystadenoma papilliferum cases (0%), 1 papillary hidradenoma (100%), 2 tubulopapillary hidradenomas (50%), 8 hidrocystomas (29%), 2 adenoid cystic carcinomas (100%), 5 porocarcinomas (20%), 6 apocrine carcinomas (33%), 10 extramammary Paget diseases (30%), 1 spiradenocarcinoma (100%), and 1 syringocystadenocarcinoma papilliferum (0%). Most KIT-positive cells were luminal cells, arising from glandular structures. We performed polymerase chain reaction–single-strand conformation polymorphism for detecting KIT mutational status. All cases showed no mutations at hot spots for KIT (exons 9, 11, 13, and 17). KIT mutation does not seem to be mechanism for KIT expression, but the expression may be from native sweat glands.
format Online
Article
Text
id pubmed-4894802
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher The American Journal of Dermatopathology
record_format MEDLINE/PubMed
spelling pubmed-48948022016-06-21 KIT (CD117) Expression in Benign and Malignant Sweat Gland Tumors Nishida, Haruto Daa, Tsutomu Kashima, Kenji Arakane, Motoki Urabe, Shogo Yoshikawa, Yasuji Gamachi, Ayako Yokoyama, Shigeo Am J Dermatopathol Original Study KIT (CD117, c-kit) is a receptor tyrosine kinase involved in the tumorigenesis of several neoplasms. KIT is expressed by the secretory cells of normal sweat glands. We studied the KIT expression and KIT mutational status in various benign and malignant tumors of eccrine and apocrine glands. We included a total of 108 cases comprising 10 benign and 6 malignant sweat gland tumors, and KIT expression was immunohistochemically detected (positive rate): 10 syringomas (0%), 8 poromas (25%), 20 mixed tumors (40%), 21 spiradenomas (43%), 1 cylindroma (0%), 5 hidradenomas (40%), 7 syringocystadenoma papilliferum cases (0%), 1 papillary hidradenoma (100%), 2 tubulopapillary hidradenomas (50%), 8 hidrocystomas (29%), 2 adenoid cystic carcinomas (100%), 5 porocarcinomas (20%), 6 apocrine carcinomas (33%), 10 extramammary Paget diseases (30%), 1 spiradenocarcinoma (100%), and 1 syringocystadenocarcinoma papilliferum (0%). Most KIT-positive cells were luminal cells, arising from glandular structures. We performed polymerase chain reaction–single-strand conformation polymorphism for detecting KIT mutational status. All cases showed no mutations at hot spots for KIT (exons 9, 11, 13, and 17). KIT mutation does not seem to be mechanism for KIT expression, but the expression may be from native sweat glands. The American Journal of Dermatopathology 2015-12 2015-11-20 /pmc/articles/PMC4894802/ /pubmed/25634571 http://dx.doi.org/10.1097/DAD.0000000000000301 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Original Study
Nishida, Haruto
Daa, Tsutomu
Kashima, Kenji
Arakane, Motoki
Urabe, Shogo
Yoshikawa, Yasuji
Gamachi, Ayako
Yokoyama, Shigeo
KIT (CD117) Expression in Benign and Malignant Sweat Gland Tumors
title KIT (CD117) Expression in Benign and Malignant Sweat Gland Tumors
title_full KIT (CD117) Expression in Benign and Malignant Sweat Gland Tumors
title_fullStr KIT (CD117) Expression in Benign and Malignant Sweat Gland Tumors
title_full_unstemmed KIT (CD117) Expression in Benign and Malignant Sweat Gland Tumors
title_short KIT (CD117) Expression in Benign and Malignant Sweat Gland Tumors
title_sort kit (cd117) expression in benign and malignant sweat gland tumors
topic Original Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894802/
https://www.ncbi.nlm.nih.gov/pubmed/25634571
http://dx.doi.org/10.1097/DAD.0000000000000301
work_keys_str_mv AT nishidaharuto kitcd117expressioninbenignandmalignantsweatglandtumors
AT daatsutomu kitcd117expressioninbenignandmalignantsweatglandtumors
AT kashimakenji kitcd117expressioninbenignandmalignantsweatglandtumors
AT arakanemotoki kitcd117expressioninbenignandmalignantsweatglandtumors
AT urabeshogo kitcd117expressioninbenignandmalignantsweatglandtumors
AT yoshikawayasuji kitcd117expressioninbenignandmalignantsweatglandtumors
AT gamachiayako kitcd117expressioninbenignandmalignantsweatglandtumors
AT yokoyamashigeo kitcd117expressioninbenignandmalignantsweatglandtumors